Seems like $AVTR is finally beginning to put prior mgmt-related headwinds in the rearview. Their showing @ JPM HC leaves me with incremental confidence in new CFO Brent Jones & the stock's associated 1-2Y multiple reversion story (trading at a ~6-8x turn discount to bioprocessing life sciences peers $TMO and $DHR). More detail to follow once I finish my model update.
@BeantownStonks Asymmetric incentive structure encourages SS to hug consensus; imagine being the one sell & getting ripped by beta. Buyside aspirations gone, sellside lifetime earnings rangebound, etc etc